Daporinad HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563394

CAS#: 1785666-54-7 (HCl)

Description: Daporinad, also known as APO-866 and FK866, is a small molecule with potential antineoplastic and antiangiogenic activities. NMPRTase inhibitor APO866 binds to and inhibits nicotinamide phosphoribosyltransferase (NMPRTase), inhibiting the biosynthesis of nicotinamide adenine dinucleotide (NAD+) from niacinamide (vitamin B3), which may deplete energy reserves in metabolically active tumor cells and induce tumor cell apoptosis. In addition, this agent may inhibit tumor cell prioduction of vascular endothelial growth factor (VEGF), resulting in the inhibition of tumor angiogenesis.

Chemical Structure

img
Daporinad HCl
CAS# 1785666-54-7 (HCl)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 563394
Name: Daporinad HCl
CAS#: 1785666-54-7 (HCl)
Chemical Formula: C24H30ClN3O2
Exact Mass: 0.00
Molecular Weight: 427.970
Elemental Analysis: C, 67.36; H, 7.07; Cl, 8.28; N, 9.82; O, 7.48

Price and Availability

Size Price Availability Quantity
10mg USD 350 2 Weeks
25mg USD 650 2 Weeks
50mg USD 1050 2 Weeks
100mg USD 1750 2 Weeks
Bulk inquiry

Related CAS #: 658084-64-1 (free base)   201034-75-5 (free base)   1785666-54-7 (HCl)   1198425-96-5 (deleted)    

Synonym: FK-866 Hydrochloride; FK 866 Hydrochloride; FK866 Hydrochloride; FK-866 HCl; FK 866 HCl; FK866 HCl; APO-866 hydrochloride; APO-866 HCl; K22.175 HCl;

IUPAC/Chemical Name: N-[4-(1-Benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide hydrochloride

InChi Key: MULSIBUGDPOSHV-CALJPSDSSA-N

InChi Code: InChI=1S/C24H29N3O2.ClH/c28-23(12-11-21-8-6-15-25-19-21)26-16-5-4-7-20-13-17-27(18-14-20)24(29)22-9-2-1-3-10-22;/h1-3,6,8-12,15,19-20H,4-5,7,13-14,16-18H2,(H,26,28);1H/b12-11+;

SMILES Code: O=C(NCCCCC1CCN(C(C2=CC=CC=C2)=O)CC1)/C=C/C3=CC=CN=C3.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: (E)-Daporinad (FK866) is an effective inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with an IC50 of 0.09 nM.
In vitro activity: In the present study, FK866 was identified to inhibit the capability of invasion and metastasis of cells from the HCC MHCC97-H line in a dose-dependent manner using a wound healing assay, an invasion assay and a migration assay. Furthermore, FK866 markedly decreased NAD+ and adenosine 5'-triphosphate content in MHCC97-H cells by inhibiting NAMPT expression. The results of the present study also revealed that FK866 led to a decrease in the expression of SIRT1, and to increased and decreased levels of the EMT marker proteins epithelial cadherin and vimentin, respectively, in MHCC97-H cells. Furthermore, FK866 inhibited the SIRT1mediated EMT, invasion and migration of HCC cells by decreasing the expression of the NAMPT/NAD+ pathway. Taken together, the results of the present study suggest that FK866 may be an effective drug targeting HCC metastasis and invasion, and that the NAMPT/NAD+/SIRT1 pathway may be a potential therapeutic target for HCC. Reference: Oncol Lett. 2018 Dec; 16(6): 7231–7238. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256367/
In vivo activity: In vivo, mice were pretreated with FK866 at 24, 12, and 0.5 h before treatment with GaIN/LPS and ConA. 3-methyladenine (3MA) or rapamycin were used to determine the role of autophagy in FK866-conferred hepatoprotection. As shown in Fig. 1f, the ATG7 and LC3B-II levels in the livers with FK866 pretreatment were higher than those without FK866 after GaIN/LPS treatment, whereas the p62 levels were lower in the FK866 + GaIN/LPS group than those in the vehicle + GaIN/LPS group. As shown in Fig. 1g, FK866 pretreatment demonstrated an increase in LC3B-II expression levels, and the administration of CQ led to further significant accumulation of LC3B-II in mice liver tissue, demonstrating that LC3B-II accumulation was not due to impaired autophagic maturation step. Taken together, these findings confirmed that FK866 could enhance hepatic autophagic activity in ALF mice models. Reference: Sci Rep. 2017; 7: 2206. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438370/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 0.0 0.00

Preparing Stock Solutions

The following data is based on the product molecular weight 427.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Guo E, Li R, Yang J, Zhang J, Li A, Yang Y, Liu S, Liu A, Jiang X. FK866 attenuates acute hepatic failure through c-jun-Nterminal kinase (JNK)-dependent autophagy. Sci Rep. 2017 May 19;7(1):2206. doi: 10.1038/s41598-017-02318-7. PMID: 28526886; PMCID: PMC5438370. 2. Zhang B, Shi D, Zhang X, Liang G, Liu W, Qiao S. FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells. Oncol Lett. 2018 Dec;16(6):7231-7238. doi: 10.3892/ol.2018.9541. Epub 2018 Oct 3. PMID: 30546461; PMCID: PMC6256367. 3. Lee J, Kim H, Lee JE, Shin SJ, Oh S, Kwon G, Kim H, Choi YY, White MA, Paik S, Cheong JH, Kim HS. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology. 2018 Sep;155(3):799-814.e13. doi: 10.1053/j.gastro.2018.05.024. Epub 2018 Jul 30. PMID: 29775598.
In vitro protocol: 1. Guo E, Li R, Yang J, Zhang J, Li A, Yang Y, Liu S, Liu A, Jiang X. FK866 attenuates acute hepatic failure through c-jun-Nterminal kinase (JNK)-dependent autophagy. Sci Rep. 2017 May 19;7(1):2206. doi: 10.1038/s41598-017-02318-7. PMID: 28526886; PMCID: PMC5438370. 2. Zhang B, Shi D, Zhang X, Liang G, Liu W, Qiao S. FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells. Oncol Lett. 2018 Dec;16(6):7231-7238. doi: 10.3892/ol.2018.9541. Epub 2018 Oct 3. PMID: 30546461; PMCID: PMC6256367.
In vivo protocol: 1. Guo E, Li R, Yang J, Zhang J, Li A, Yang Y, Liu S, Liu A, Jiang X. FK866 attenuates acute hepatic failure through c-jun-Nterminal kinase (JNK)-dependent autophagy. Sci Rep. 2017 May 19;7(1):2206. doi: 10.1038/s41598-017-02318-7. PMID: 28526886; PMCID: PMC5438370. 2. Lee J, Kim H, Lee JE, Shin SJ, Oh S, Kwon G, Kim H, Choi YY, White MA, Paik S, Cheong JH, Kim HS. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology. 2018 Sep;155(3):799-814.e13. doi: 10.1053/j.gastro.2018.05.024. Epub 2018 Jul 30. PMID: 29775598.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Qu SD, Liu GX. Daporinad in vitro metabolite profiling via rat, dog, monkey and human liver microsomes by liquid chromatography/quadrupole-orbitrap mass spectrometry. Rapid Commun Mass Spectrom. 2021 Sep 30;35(18):e9150. doi: 10.1002/rcm.9150. PMID: 34159659.


2: Park M, Lee BI, Choi J, Park Y, Park SJ, Lim JH, Lee J, Shin YG. Quantitative Analysis of Daporinad (FK866) and Its In Vitro and In Vivo Metabolite Identification Using Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Molecules. 2022 Mar 21;27(6):2011. doi: 10.3390/molecules27062011. PMID: 35335372; PMCID: PMC8954816.


3: Shen Y, Wei Z, Zhou C, Song J, Wang J, Wang J, Wu L, Fang S, Shen Z. Arylsulfatase I is a prognostic biomarker for head and neck squamous cell carcinoma and Pan-cancer. J Clin Lab Anal. 2022 Sep;36(9):e24600. doi: 10.1002/jcla.24600. Epub 2022 Jul 23. PMID: 35870182; PMCID: PMC9459304.


4: Peng Q, Jia SH, Parodo J, Ai Y, Marshall JC. Pre-B cell colony enhancing factor induces Nampt-dependent translocation of the insulin receptor out of lipid microdomains in A549 lung epithelial cells. Am J Physiol Endocrinol Metab. 2015 Feb 15;308(4):E324-33. doi: 10.1152/ajpendo.00006.2014. Epub 2014 Dec 16. PMID: 25516545.


5: Sauriol A, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, Oza AM, Lheureux S, Provencher DM, Mes-Masson AM. Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer. Sci Rep. 2023 Feb 27;13(1):3334. doi: 10.1038/s41598-023-30081-5. PMID: 36849518; PMCID: PMC9970983.